Previous Close | 17.39 |
Open | 17.31 |
Bid | 17.26 x 2900 |
Ask | 19.47 x 800 |
Day's Range | 17.30 - 17.76 |
52 Week Range | 10.02 - 20.43 |
Volume | 7,288 |
Avg. Volume | 34,385 |
Market Cap | 205.824M |
Beta (5Y Monthly) | 1.08 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -7.70 |
Earnings Date | Mar 11, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 27.75 |
, March 23, 2021 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, granted a stock option to a new employee as approved by the Compensation Committee of the Company's Board of Directors, under Sierra Oncology's 2018 Equity Inducement Plan.
A look at the shareholders of Sierra Oncology, Inc. ( NASDAQ:SRRA ) can tell us which group is most powerful. Insiders...
Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operational results for the fourth quarter and fiscal year ended December 31, 2020.